AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31237571 — intervention group
Group type: COMPARATOR
Intervention: Traditional Loss of Resistance (LOR)
Number of subjects: 400
Study 28591778 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D_M0,6 (2-dose schedule at months 0 and 6)
Number of subjects: 0
Study 28591778 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D_M0,12 (2-dose schedule at months 0 and 12)
Number of subjects: 0
Study 28591778 — intervention group
Group type: COMPARATOR
Intervention: 3D_M0,1,6 (3-dose schedule at months 0, 1, and 6)
Number of subjects: 0
Study 26114996 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention with diabetes educators videoconferencing monthly to review glucose and blood pressure readings.
Number of subjects: 0
Study 26114996 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing medication dose (as opposed to starting or stopping a medication).
Number of subjects: 0
Study 26114996 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusting glucose-lowering agents compared with antihypertensive or antilipid medications.
Number of subjects: 0
Study 26114996 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total Diabetes Symptom Checklist-Type 2 symptom severity score.
Number of subjects: 0
Study 26114996 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of glucose readings submitted by participants.
Number of subjects: 0
Study 26114996 — intervention group
Group type: EXPERIMENTAL
Intervention: High score on surveys measuring impact of telemedicine on patient's knowledge, adherence, and satisfaction.
Number of subjects: 0
Study 24096188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored exercise training and diet counseling program
Number of subjects: 264
Study 24096188 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no lifestyle intervention)
Number of subjects: 264
Study 21640651 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (5 mg/h)
Number of subjects: 1157
Study 21640651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study 19486720 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents
Number of subjects: 10727
Study 16818012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination neoadjuvant chemotherapy
Number of subjects: 0
Study 16818012 — intervention group
Group type: COMPARATOR
Intervention: Local therapy alone
Number of subjects: 0
Study 16818012 — intervention group
Group type: COMPARATOR
Intervention: Delay of cystectomy beyond 12 weeks
Number of subjects: 0
Study 16818012 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cystectomy with adjuvant chemotherapy
Number of subjects: 0
Study 16818012 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with monitoring of response
Number of subjects: 0
Study 15373236 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 54
Study 15373236 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 54
Study 9029036 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated rG-CSF (lenograstim)
Number of subjects: 30
Study 9029036 — intervention group
Group type: COMPARATOR
Intervention: Nonglycosylated rG-CSF (filgrastim)
Number of subjects: 30
Study 7879749 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting at friends' residence
Number of subjects: 630
Study 7879749 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting in shooting galleries
Number of subjects: 630
Study 7879749 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting in semipublic areas
Number of subjects: 630
Study 7879749 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of injecting with others
Number of subjects: 630
Study 2843255 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin + dihydroergotamine (A)
Number of subjects: 356
Study 2843255 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin + dihydroergotamine (B)
Number of subjects: 356
Study 2843255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 356
Study 2843255 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 356
Study 31420748 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg IR on awakening QD
Number of subjects: 565
Study 31420748 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg DR following breakfast QM
Number of subjects: 565
Study 31420748 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg DR following breakfast QM
Number of subjects: 565
Study 31420748 — intervention group
Group type: EXPERIMENTAL
Intervention: DR groups (25 mg and 37.5 mg)
Number of subjects: 565
Study 31420748 — intervention group
Group type: COMPARATOR
Intervention: IR group
Number of subjects: 565
Study 31201692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (20 ml of 2.5% bupivacaine hydrochloride)
Number of subjects: 130
Study 31201692 — intervention group
Group type: COMPARATOR
Intervention: Control (0 ml of bupivacaine)
Number of subjects: 130
Study 31201692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine
Number of subjects: 130
Study 31201692 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study 28410453 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 20
Study 28410453 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 20
Study 24983707 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Counseling
Number of subjects: 130
Study 24983707 — intervention group
Group type: COMPARATOR
Intervention: Contact Control
Number of subjects: 130
Study 23741350 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (21 microg/kg)
Number of subjects: 22
Study 23741350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22125893 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hypnosis in addition to conventional medical management
Number of subjects: 0
Study 22125893 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management without hypnosis
Number of subjects: 0
Study 19672175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (8 mg/ml)
Number of subjects: 104
Study 19672175 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (100 microg/ml)
Number of subjects: 104
Study 16139450 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/hormone therapy (ET/HT) for 3 years
Number of subjects: 489
Study 16139450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 16139450 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/hormone therapy (ET/HT)
Number of subjects: 489
Study 15640848 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine
Number of subjects: 876
Study 15640848 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 876
Study 11130166 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide (two drops in one eye)
Number of subjects: 35
Study 11130166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two drops in the other eye)
Number of subjects: 35
Study 9311511 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol inhaled at high flow rate (120 L.min-1)
Number of subjects: 16
Study 9311511 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol inhaled at low flow rate (60 L.min-1)
Number of subjects: 16
Study 9311511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8318319 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 60
Study 8318319 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 5 micrograms ml‐1
Number of subjects: 60
Study 8318319 — intervention group
Group type: EXPERIMENTAL
Intervention: combined group (0.125% bupivacaine with fentanyl 5 micrograms ml‐1)
Number of subjects: 60
Study 8318319 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine group
Number of subjects: 60
Study 8318319 — intervention group
Group type: COMPARATOR
Intervention: fentanyl group
Number of subjects: 60
Study 8318319 — intervention group
Group type: EXPERIMENTAL
Intervention: knee replacement
Number of subjects: 60
Study 3544938 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-scopolamine (TTS-s)
Number of subjects: 59
Study 3544938 — intervention group
Group type: COMPARATOR
Intervention: TTS-placebo (TTS-p)
Number of subjects: 59
Study 31693541 — intervention group
Group type: EXPERIMENTAL
Intervention: GET Living (graded exposure treatment)
Number of subjects: 27
Study 30183414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facilitated physical activity intervention (PAI)
Number of subjects: 50
Study 30183414 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 50
Study 26386732 — intervention group
Group type: EXPERIMENTAL
Intervention: In-centre nocturnal hemodialysis (INHD)
Number of subjects: 67
Study 24907643 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI+CFAE group (n = 35)
Number of subjects: 68
Study 24907643 — intervention group
Group type: COMPARATOR
Intervention: PVI-alone group (n = 33)
Number of subjects: 68
Study 24907643 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (PVI-alone vs PVI+CFAE)
Number of subjects: 68
Study 22573599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) for 7 weeks
Number of subjects: 272
Study 22573599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 272
Study 21981842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with rosuvastatin 20 mg and fenofibric acid 135 mg
Number of subjects: 2182
Study 21981842 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin monotherapy (10, 20, or 40 mg)
Number of subjects: 2182
Study 21981842 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 5, 10, 20, or 40 mg; fenofibric acid 135 mg
Number of subjects: 2182
Study 19092614 — intervention group
Group type: EXPERIMENTAL
Intervention: OP-1 Putty
Number of subjects: 335
Study 19092614 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autograft
Number of subjects: 335
Study 16908870 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 36
Study 16908870 — intervention group
Group type: COMPARATOR
Intervention: Responsive Education and Prelinguistic Milieu Teaching (RPMT)
Number of subjects: 36
Study 14666012 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg Salvia miltiorrhiza intravenously after anesthesia induction and at the time of rewarming (n=10)
Number of subjects: 20
Study 14666012 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (n=10)
Number of subjects: 20
Study 10705191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiuggi mineral water (oligomineral water with a calcium content of 15 mg/l)
Number of subjects: 384
Study 10705191 — intervention group
Group type: COMPARATOR
Intervention: Tap water (calcium content ranging between 55 and 130 mg/l)
Number of subjects: 384
Study 9023787 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (375 mg/day for 10 days, then reduced to 150 mg/day)
Number of subjects: 167
Study 9023787 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (200 mg/day)
Number of subjects: 167
Study 9023787 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 167
Study 9023787 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 167
Study 1670783 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine-decongestant
Number of subjects: 96
Study 1670783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 1670783 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 96
Study 6182075 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal modalities and transcutaneous electrical nerve stimulation for pain control
Number of subjects: 0
Study 6182075 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 0
Study 6182075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory assistive devices
Number of subjects: 0
Study 6182075 — intervention group
Group type: EXPERIMENTAL
Intervention: Below the knee bearing braces
Number of subjects: 0
Study 6182075 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive and corrective footwear and shoe modification
Number of subjects: 0
Study 30790557 — intervention group
Group type: EXPERIMENTAL
Intervention: HABIT-ILE (hand-arm bimanual intensive therapy) delivered over 2 weeks
Number of subjects: 41
Study 30790557 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (mostly neurodevelopmental) delivered 1-5 times/week
Number of subjects: 41
Study 28379310 — intervention group
Group type: EXPERIMENTAL
Intervention: E/A ratio increase (per 0.1 increase)
Number of subjects: 573
Study 28379310 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume increase (per 5 mL increase)
Number of subjects: 573
Study 28379310 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial area increase (per 5 cm2 increase)
Number of subjects: 573
Study 28379310 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak A wave velocity increase (per 10 cm/s increase)
Number of subjects: 573
Study 28379310 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak A wave velocity adjusted for left atrial volume
Number of subjects: 573
Study 28379310 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume adjusted for peak A wave velocity
Number of subjects: 573
Study 28379310 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial area adjusted for peak A wave velocity
Number of subjects: 573
Study 26535967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg bid)
Number of subjects: 210
Study 26535967 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR (20-50 mg bid)
Number of subjects: 210
Study 26535967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 210
Study 26535967 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR
Number of subjects: 210
Study 23493606 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 20 µg/DRSP 3 mg (flexible extended regimen)
Number of subjects: 1100
Study 23493606 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 20 µg/DRSP 3 mg (conventional 28-day cyclic regimen)
Number of subjects: 1100
Study 23493606 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 20 µg/DRSP 3 mg (fixed extended regimen)
Number of subjects: 1100
Study 20875905 — intervention group
Group type: EXPERIMENTAL
Intervention: CFF to red stimuli in patients with optic neuritis related to multiple sclerosis
Number of subjects: 0
Study 20875905 — intervention group
Group type: EXPERIMENTAL
Intervention: CFF to blue stimuli in patients with diabetic retinopathy
Number of subjects: 0
Study 20875905 — intervention group
Group type: COMPARATOR
Intervention: CFF values in healthy subjects
Number of subjects: 0
Study 19436647 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with thrombectomy
Number of subjects: 0
Study 19436647 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) without thrombectomy
Number of subjects: 0
Study 17420364 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical beta-adrenergic antagonists
Number of subjects: 727
Study 17420364 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues
Number of subjects: 727
Study 15547470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriasert insert
Number of subjects: 72
Study 15547470 — intervention group
Group type: COMPARATOR
Intervention: Eye drops (active control)
Number of subjects: 72
Study 12467106 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg glucose
Number of subjects: 0
Study 12467106 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 0
Study 12467106 — intervention group
Group type: COMPARATOR
Intervention: saccharin (placebo)
Number of subjects: 0
Study 9117888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) infusion
Number of subjects: 8
Study 9117888 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 8
Study 7892364 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 82
Study 7892364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 7892364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 82
Study 7892364 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 82
Study 3025246 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) infusion
Number of subjects: 0
Study 3025246 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (NS) infusion
Number of subjects: 0
Study 3025246 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH administration during saline infusions
Number of subjects: 0
Study 28476901 — intervention group
Group type: COMPARATOR
Intervention: Education on symptoms management and training modifications (education)
Number of subjects: 69
Study 28476901 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme in addition to education (exercises)
Number of subjects: 69
Study 28476901 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining in addition to education (gait retraining)
Number of subjects: 69
Study 28296588 — intervention group
Group type: EXPERIMENTAL
Intervention: AppleMetS® (AMS), 2 capsules a day for one month
Number of subjects: 0
Study 26202924 — intervention group
Group type: EXPERIMENTAL
Intervention: G5 culture medium
Number of subjects: 20
Study 26202924 — intervention group
Group type: COMPARATOR
Intervention: HTF culture medium
Number of subjects: 20
Study 24015630 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidal hypertrophy group
Number of subjects: 141
Study 24015630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 21435021 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% retinyl retinoate cream for 3 months
Number of subjects: 11
Study 21435021 — intervention group
Group type: COMPARATOR
Intervention: 0.075% retinol cream
Number of subjects: 11
Study 18339027 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT-G 'In Tube' assay
Number of subjects: 191
Study 18339027 — intervention group
Group type: COMPARATOR
Intervention: TST
Number of subjects: 191
Study 18339027 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT-G 'In Tube' assay and TST
Number of subjects: 191
Study 16887890 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 0
Study 16887890 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 16887890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of disulfiram and naltrexone
Number of subjects: 0
Study 16887890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14612213 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 70
Study 14612213 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 70
Study 14612213 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 70
Study 10809907 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (5 microg kg‐1 12 h prior to surgery plus 5 microg kg‐1 0 h prior to surgery)
Number of subjects: 24
Study 10809907 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 24
Study 10809907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8608540 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HF) at doses of 64.8, 72, 76.8, or 81.6 Gy
Number of subjects: 786
Study 8608540 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy (AHF) at doses of 48 or 54.4 Gy
Number of subjects: 786
Study 8608540 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) administered with both HF and AHF
Number of subjects: 786
Study 1447500 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 36
Study 1447500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6142716 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study 6142716 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 0
Study 6142716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30806856 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed poultice compress
Number of subjects: 82
Study 30806856 — intervention group
Group type: COMPARATOR
Intervention: Hot compress
Number of subjects: 82
Study 30806856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 82
Study 27618639 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (homework‐focused parent training and a daily report card; BPT + DRC)
Number of subjects: 75
Study 27618639 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 75
Study 26527162 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable magnesium screws and vascularized iliac grafting
Number of subjects: 19
Study 23380213 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal instrument-based manipulative treatments (9 treatments over 2 weeks)
Number of subjects: 11
Study 23380213 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (asymptomatic group, n = 10, 6 males, 4 females)
Number of subjects: 11
Study 21955527 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed invitation (paper-based questionnaire together with log-in details for Web-based questionnaire)
Number of subjects: 277
Study 21955527 — intervention group
Group type: COMPARATOR
Intervention: Web-only invitation (log-in details only)
Number of subjects: 277
Study 19535430 — intervention group
Group type: EXPERIMENTAL
Intervention: Food plus water intake
Number of subjects: 35
Study 19535430 — intervention group
Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 35
Study 16546771 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intensive basketball training program for 8 weeks
Number of subjects: 62